CN102010512A - Preparation method and application of water-soluble chitosan micro-particles - Google Patents
Preparation method and application of water-soluble chitosan micro-particles Download PDFInfo
- Publication number
- CN102010512A CN102010512A CN2010105058496A CN201010505849A CN102010512A CN 102010512 A CN102010512 A CN 102010512A CN 2010105058496 A CN2010105058496 A CN 2010105058496A CN 201010505849 A CN201010505849 A CN 201010505849A CN 102010512 A CN102010512 A CN 102010512A
- Authority
- CN
- China
- Prior art keywords
- water
- soluble chitosan
- wsc
- preparation
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000011859 microparticle Substances 0.000 title abstract 5
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 19
- 230000036528 appetite Effects 0.000 claims abstract description 9
- 235000019789 appetite Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 20
- 230000006196 deacetylation Effects 0.000 claims description 15
- 238000003381 deacetylation reaction Methods 0.000 claims description 15
- 238000001694 spray drying Methods 0.000 claims description 8
- 210000000577 adipose tissue Anatomy 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229920000554 ionomer Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 39
- 239000002105 nanoparticle Substances 0.000 abstract description 27
- 150000002632 lipids Chemical class 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 36
- 239000003925 fat Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000002245 particle Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000037396 body weight Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002572 peristaltic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000013065 commercial product Substances 0.000 description 3
- 210000002468 fat body Anatomy 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000010494 opalescence Effects 0.000 description 3
- 235000019830 sodium polyphosphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 108010054033 Chitin deacetylase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of water-soluble chitosan micro-particles. The water-soluble chitosan micro-particles comprise water-soluble chitosan micro-spheres and water-soluble chitosan nano-particles. The invention provides the application of the water-soluble chitosan micro-particles in preparing weight-loss or lipid lowering medicaments or foods. It is summarized through researches that when applied to the preparation of medicaments or foods for inhibiting appetite or reducing internal fat, the water-soluble chitosan micro-particles have a good effect. The invention provides a technical support for better applying water-soluble chitosan to the preparation of the foods or the medicaments for losing weight, realizing effective reduction of food feeding quantity or administration dosage, and obtaining a good weight-losing effect.
Description
Technical field
The invention belongs to medicine and functional foodstuff technical field, be specifically related to a kind of preparation and application thereof of water-soluble chitosan particulate.
Background technology
Chitosan (CTS) is to make by the chitin deacetylase base, is a kind of natural positively charged ion saccharan, is present in a large number in the crust of ocean arthropods (shrimp, crab etc.), also is present in lower animal mushroom, insect, the alga cells film, and resource is very abundant.Chitosan itself has positive charge can combine it with fat that has negative charge and bile acide etc.; Chitosan can also by hydrophobic bond and neutral fat combine emulsification they.A large amount of animal and human's body test-results proof chitosans can obviously reduce cholesterol and lipid content in the blood.
Even at present most researchers think chitosan as a kind of food fibre and foodstuff additive to the almost non-toxic side effect of human body, but many reports show that a large amount of edible chitosans still may cause constipation, stomachache, vomiting, untoward reaction such as feel sick.So, need to seek a kind of feasible method and solve chitosan dosage and side-effect problem in use.Because common chitosan can only be dissolved in the weakly acidic solution, can not be soluble in water, cause chitosan low, need the long period in human body, to dissolve the effect of competence exertion Weight-reducing and lipid-lowering afterwards, bring inconvenience for taking of chitosan the joint efficiency of fat and cholate.
Simultaneously, in the prior art, chitosan all is wall material or the auxiliary material as preparation other drug particulate usually, adopts water to add the preparation of oil phase emulsification method, owing to used a large amount of initiators and organic solvent in the emulsion polymerization method preparation process, can introduce toxicity.
Water-soluble chitosan (WSC) is the derivative of chitosan, and it can be well soluble in water, demonstrated the advantageous property that common chitosan does not have.Studies show that much that at present the common chitosan of energy force rate of water-soluble chitosan reducing cholesterol and absorbing fats is stronger.The applicant discloses chitosan, water-soluble chitosan microballoon and nanoparticle in number of patent application is 200910214313.6 and 200910214314.0 patent application, adopt direct preparation method to prepare, and its application aspect reducing blood-fat is provided.But, 200910214313.6 and the research that provides of 200910214314.0 patent application based on be hyperlipidemia animal model rather than fat model, according to art technology general knowledge, hyperlipidemia model and fat model are all existing significant difference aspect the physiology and the mechanism of action, though the experimental summary that the above-mentioned technical study achievement of the applicant successfully is applied to the lipopenicillinase model by chitosan and water-soluble chitosan particulate obtains the blood lipid level that chitosan and water-soluble chitosan particulate can well reduce hyperlipidemia rats, can be applicable to prepare fat-reducing medicament or food aspect, whether can not be applied to prepare and have the medicine that reduces body weight or the effect of food aspect but relate to it.Along with the continuous quickening of present rhythm of life, reduce body weight or fat-reducing and belong to a special and technical study field independently, demand is extremely urgent.
Simultaneously, existing result of study has shown that all the particle diameter of water-soluble chitosan is when diminishing, because the rapid increase of surface-area is absorbing fats and lipid acid more, finally can better reduce cholesterol and fat in the blood, result of study shows that particle diameter is more little, and the water-soluble chitosan action effect is good more.
Summary of the invention
The objective of the invention is to overcome the deficiency of existing water-soluble chitosan particulate utilisation technology, provide a kind of water-soluble chitosan particulate new application, described water-soluble chitosan particulate comprises water-soluble chitosan microballoon and water-soluble chitosan nanoparticle.The invention provides described water-soluble chitosan microballoon and nanoparticle new utilisation technology scheme aspect preparation fat-reducing or auxiliary antilipemic food or medicine.
The present invention adopts spray drying method for preparation water-soluble chitosan microballoon.Water-soluble chitosan is carried out spraying drying with deionized water dissolving, after being placed to no bubble, promptly get the water-soluble chitosan microballoon.The drying process with atomizing condition: temperature in is 140～190 ℃, and temperature out is 80～100 ℃, and peristaltic pump speed is 300～1000ml/h, compressed air pressure 100～150kPa, nozzle diameter 0.7mm.
Described water-soluble chitosan nanoparticle is that the method that adopts ionomer, spray-drying process to combine prepares.It is an amount of to take by weighing water-soluble chitosan, is mixed with certain quality concentration with deionized water dissolving; It is an amount of that other gets sodium polyphosphate, is dissolved in the deionized water of certain volume; Under continuous stirring condition, slowly drip the polyphosphoric acid sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back adopt spray-drying process to volatilize solvent, obtain the solid of water-soluble chitosan nanoparticle.The drying process with atomizing condition: temperature in is 140～180 ℃, and temperature out is 80～100 ℃, and peristaltic pump speed is 300～1000ml/h, compressed air pressure 100～150kPa, nozzle diameter 0.5mm.
It is to carry out under 60～80 ℃ of temperature control conditions that evaporation concentration is revolved in above-mentioned commentaries on classics, nanometer suspension liquid is evaporated to volume is reduced to original half and gets final product.
Prior art comprises that number of patent application is 200910214313.6 patent application, the water-soluble chitosan raw material is not carried out more deep research, sum up through long-term a large amount of experimental study and analysis, the factor that influences water-soluble chitosan fat-reducing effect not only has relation with the particle diameter of water-soluble chitosan, and more deacetylation and the molecular weight with water-soluble chitosan has direct relation.
The present invention is by long-term lot of experiments, and summary obtains: the water-soluble chitosan deacetylation 60%～99% and molecular weight have certain antiobesity action 1～3,000,000.Can realize better that the technical scheme of the object of the invention is: in the application of water-soluble chitosan particulate of the present invention aspect preparation slimming medicine or food, raw material is optimized, preferably adopt the deacetylation scope be 85%～99% and molecular weight be that 10～500,000 water-soluble chitosan prepares the water-soluble chitosan particulate.
The application of water-soluble chitosan provided by the invention aspect preparation fat-reducing or fat-reducing medicament or food, specifically aspect the medicine or foodstuff applications of preparation fat-reducing, the water-soluble chitosan microballoon (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
Aspect the medicine or food of preparation depress appetite, the water-soluble chitosan microballoon (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
Aspect preparation minimizing body fat medicine or foodstuff applications, the water-soluble chitosan microballoon (WSC-MP) and the water-soluble chitosan nanoparticle (WSC-NP) that can adopt the present invention to prepare, preferred WSC-MP.
The invention has the beneficial effects as follows:
The present invention constantly attempts water-soluble chitosan be applied to the to lose weight technique effect in field and sum up, but a large amount of experiment shows that effect is indeterminate also unstable when constantly summing up the utilisation technology effect of water-soluble chitosan aspect reducing blood-fat.The present invention has at first carried out systematic research to the deacetylation of raw material one water-soluble chitosan of preparation water-soluble chitosan particulate and the influence of molecular weight, draw the raw material scheme that can obtain stable significantly fat-reducing and lipid-lowering effect, the technical scheme that provides the preparation aspect more to optimize pointedly to existing water-soluble chitosan;
The more important thing is, according to art technology general knowledge, usually the water-soluble chitosan diameter of particle is more little, specific surface area also increases greatly, help absorbing fats and lipid acid more, finally can better reduce intravital cholesterol and fat, but the practical application effect data are also unstable and can have regularity, this brings huge obstruction for applying of water-soluble chitosan.The present invention has studied the important factor in order of water-soluble chitosan particulate in the fat-reducing application facet, summary obtains the influence of different-grain diameter variation to the water-soluble chitosan effect, prove through lot of experiments, overcome the difficulty of modeling, obtain by creationary analysis and experimental summary, in important fat-reducing Application Areas, comprise the medicine or the food aspect of preparation depress appetite, fat-reducing, minimizing body fat, the effect of water-soluble chitosan microballoon all is better than the water-soluble chitosan nanoparticle.The present invention has overcome the prejudice of technology thinking set and prior art, provides technical foundation and support for better developing water-soluble chitosan.Thus, the invention provides water-soluble chitosan preparation aspect the fat-reducing food or the new application scheme of medicine.
Embodiment.
Further describe the present invention below in conjunction with specific embodiment.Employed test method is ordinary method if no special instructions among the following embodiment; Employed material, reagent etc. if no special instructions, are the reagent and the material that can obtain from commercial channels.
The preparation of embodiment 1 water-soluble chitosan microballoon
Take by weighing 27.2g water-soluble chitosan (according to self-control of existing method or commercial product, molecular weight is 10～300,000, and deacetylation is 85%～99%) and be added to that mechanical stirrer stirs in the 1800ml deionized water, carry out spraying drying after being placed to no bubble; Use homemade L-117 type laboratory spray-drier (the next prosperous science and trade in Beijing limited liability company, also can adopt other producer's similar devices) preparation micron grain, preparation process is used the nozzle of standard 0.7mm, 160 ℃ of drying tower inlet temperature, 80～85 ℃ of temperature outs, hot air flow 90% (about 35m
3/ h), peristaltic pump flow 50% (about 600ml/h), compressed air pressure 120kPa.The preparation method also can be 200910214313.6 preparation scheme with reference to the applicant at number of patent application.
Prepare 16.6g water-soluble chitosan microballoon, productive rate is 61.2%.Use laser particle analyzer (Britain also can adopt other producer's similar devices for Zetasizer 3000HAS, Ma Erwen instrument company) that its particle diameter is measured, median size is 2 μ m.
The preparation of embodiment 2 water-soluble chitosan microballoons
Get the 28g water-soluble chitosan (according to existing method self-control or commercial product, molecular weight is 20～300,000, deacetylation is 80%～85%) be added in the 1800ml deionized water mechanical stirrer and stir, after being placed to no bubble, spray drying method for preparation micron grain, preparation process is used the nozzle of standard 0.7mm, 190 ℃ of drying tower inlet temperature, 85～90 ℃ of temperature outs, hot air flow 90% (about 35m
3/ h), peristaltic pump flow 500ml/h, compressed air pressure 100kPa.
Prepare 17.4g water-soluble chitosan microballoon, productive rate is 62.3%.Use laser particle analyzer that its particle diameter is measured, median size is 1.58 μ m.
The preparation of embodiment 3 water-soluble chitosan microballoons
Get 27.2g water-soluble chitosan (according to existing method self-control or commercial product, molecular weight is 40～500,000, deacetylation 60%～80%), other experimental techniques are with embodiment 1.
Prepare 16.9g water-soluble chitosan microballoon, productive rate is 62.1%.Use laser particle analyzer that its particle diameter is measured, median size is 1.32 μ m.
The preparation of embodiment 4 water-soluble chitosan nanoparticles
Take by weighing water-soluble chitosan (molecular weight is 10～500,000, deacetylation be 85%～99%) 25g, use the 10000ml deionized water dissolving; Other gets sodium polyphosphate 2.5g, is dissolved in the 2500ml deionized water; Under continuous stirring condition, slowly drip the polyphosphoric acid sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back volatilize solvent with spray-drying process, obtain the solid of water-soluble chitosan nanoparticle, described rotary evaporation concentrates with reference to ordinary method, is concentrated into volume and reduces about 1/2.
Described drying process with atomizing condition: temperature in is 140 ℃, and temperature out is 85 ℃, and peristaltic pump speed is 600ml/h, compressed air pressure 120kPa, nozzle diameter 0.5mm.
Prepare 17.9g water-soluble chitosan nanoparticle, productive rate is 65%.Use laser particle analyzer that its particle diameter is measured, median size is 500～1000nm.
The preparation of embodiment 5 water-soluble chitosan nanoparticles
Take by weighing water-soluble chitosan (molecular weight is 20～500,000, deacetylation be 85%～99%) 30g, use the 10000ml deionized water dissolving; Other gets sodium polyphosphate 3g, is dissolved in the 3000ml deionized water; Under continuous stirring condition, slowly drip the polyphosphoric acid sodium solution in water-soluble chitosan solution, until blue opalescence occurring, promptly get the suspension of water-soluble chitosan nanoparticle; This suspension rotary evaporation is concentrated the back volatilize solvent with spray-drying process, obtain the solid of water-soluble chitosan nanoparticle, described rotary evaporation concentrates with reference to ordinary method, is concentrated into volume and reduces about 1/2.
Described drying process with atomizing condition: temperature in is 180 ℃, and temperature out is 85 ℃, and peristaltic pump speed is 400ml/h, compressed air pressure 150kPa, nozzle diameter 0.5mm.
Prepare 21.9g water-soluble chitosan nanoparticle, productive rate is 66.4%.Use laser particle analyzer that its particle diameter is measured, median size is 800～1000nm.
The preparation of embodiment 6 water-soluble chitosan nanoparticles
Adopt that molecular weight is 50,000, deacetylation is 70% water-soluble chitosan, other experiment conditions are with embodiment 5.
Prepare the 15.8g chitosan nano, productive rate is 48%.Use laser particle analyzer that its particle diameter is measured, median size is 500nm.
Embodiment 7 application experiments
(1) test materials
Present embodiment with deacetylation be 85～99% and molecular weight be that 10～500,000 water-soluble chitosan is a raw material, prepare water-soluble chitosan microballoon and water-soluble chitosan nanoparticle as the application experiment material according to the method for the invention.
The high lipid food prescription: basal feed (commercial) 80%, yolk powder (commercial) 10%, lard (commercial) 10% is mass percent.
Physiological saline.
Use 90 of male SD rats, body weight 200 ± 20g (purchasing Experimental Animal Center) in the experiment in Guangdong Province.Raising in temperature and humidity keeps the constant room, free diet.
(2) experimentation
Rat adaptability was raised after 7 days, was divided into 9 groups (n=10) at random: normal physiological saline control group (NF), high lipoprotein emulsion control group (HF), water-soluble chitosan control group (WSC), water-soluble chitosan microballoon treatment group heavy dose (H-WSC-MP), dosage (M-WSC-MP) in the water-soluble chitosan microballoon treatment group, water-soluble chitosan microballoon treatment group low dose (L-WSC-MP), water-soluble chitosan nanoparticle treatment group heavy dose (H-WSC-NP), dosage (M-WSC-NP) in the water-soluble chitosan nanoparticle treatment group, water-soluble chitosan nanoparticle treatment group low dose (L-WSC-NP).
Weekly the mouse body weight is weighed twice and record in the experimentation; Every rat of every day record give appetite, surplus appetite, berley amount.The edible common commercially available rat feed of NF group finishes up to experiment, and the edible high lipid food of HF group finishes up to experiment; In other group every day in edible 4 weeks of high lipid food, the WSC control group is irritated stomach respectively every day and is accepted the 250mg/kg water-soluble chitosan in 4 weeks subsequently; H-WSC-MP group and H-WSC-NP group are irritated stomach respectively and accept 500mg/kg water-soluble chitosan microballoon and nanoparticle every days, and M-WSC-MP group and M-WSC-NP organize and irritate stomach every day and accept 250mg/kg water-soluble chitosan microballoon and nanoparticle; L-WSC-MP group and L-WSC-NP organize and irritate stomach every day and accept 125mg/kg water-soluble chitosan microballoon and nanoparticle.The equal free diet of all group rats does not add control.
After experiment finishes, the equal fasting of all rats one day.Behind the etherization, the kapillary eye socket is got blood system and is loaded on common centrifuge tube and anti-freezing centrifuge tube.All rats are all dissected subsequently, get perirenal fat, testis week fat and weighing.
Get not the blood handled through anti-freezing under the 3000r/min condition centrifugal 15 minutes, getting top serum uses test kit at automatic biochemical analyzer (AMS-18, Beijing Ao Pusen technology ﹠ development Co., China also can adopt other producer's similar devices) last total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) (HDL-C), the low-density lipoprotein of measuring in the serum (LDL-C).
The blood that the anti-freezing of learning from else's experience is handled is surveyed its viscosity with whole blood viscosity determinator (China also can adopt other producer's similar devices for LBY-N6B, Pulisheng Instruments Co., Ltd., Beijing).
(3) toxicity test
200 of the NIH mouse of cleaning level, body weight is between 18～22g, and state of health is good, and male and female half and half are provided by Guangdong Medical Lab Animal Center.The laboratory animal certification of fitness: SCXK (Guangdong) 2008-0002.The experiment mice male and female are divided cage, and the foot food is fed, freely drink water, and 18 ℃～22 ℃ of room temperatures, laboratory relative humidity is 55～70%.
According to the character of being tried thing and given data, the dosage of general many employings 0.1,1.0 and 10.0g/kgBW, each is with 2～3 animal preruns.According to death condition in the 24h, estimate LD
50The possible range of (adopting engler's assay method suddenly) is determined the dosage of official test.Also can adopt a dosage simply,,, observe the poisoning manifestations of animal in the 2h with 5 animal preruns as 215mg/kgBW.As serious symptom, estimate that most animals may be dead, can adopt the dosage series that is lower than 215mg/kgBW, otherwise symptom is lighter, then can adopt the dosage series that is higher than this dosage.This experiment adopts the 10.0g/kgBW dosage condition of carrying out to grope.Give mouse stomach 10% (g/100mL) WSC-MP and WSC-NP suspension.Final definite dosage range is at 1.0～10.0g/kgBW.
60 of NIH kind mouse are got in official test, and male and female half and half are divided into 3 groups at random, WSC group, WSC-MP group, WSC-NP group, 20 every group, male and female half and half.Every group by 1000,2150,4640,4 dosage of 10000mg/kg carry out administration, each dosage uses 5 experiment mices.
More than the preceding fasting 12h of experiment, with WSC, WSC-MP, 3 sample suspensions of WSC-NP, each sample respectively by 1000,2150,4640,4 dosage of 10000mg/kg BW carry out gastric infusion, peak concentration is that 100mg/mL is (just by irritating the stomach syringe needle, do not cause the concentration that former pharmacology voltinism shape changes), maximum volume is 0.8mL/20mg.The experiment back is observed the death condition that is produced in the 7d continuously.Notice whether mouse spirit, activity, diet abnormal conditions occur in the 7d after being subjected to the reagent thing.For the mouse of death the anatomic observation heart, liver, spleen, lung, kidney etc. immediately, record pathology situation.Observe following index in the experimentation simultaneously:
Breathe and cardiovascular: comprise and being short of breath or slow, nose is secreted with excessivelying that it is fast etc. to touch the pareordia heart rate;
Urogenital system: comprise labia, mammary gland swelling, perineal position dirt etc.;
Skin and hair color: comprise color, integrity, have not congested, cyanosis is pale, dermexanthesis, fur are loose etc.;
Eyes: blepharoptosis, ophthalmoptosis, tremble etc.; Comprising that pupil has does not dwindle or amplifies, and the stream birth, sheds tears etc.
Select 60 of the healthy cleaning level of body weight 18～22g NIH kind mouse for use, be divided into 3 groups at random, promptly WSC organizes, WSC-MP organizes, the WSC-NP group, every group of 20 mouse, male and female half and half.Fasting is 12 hours before the administration.WSC, WSC-MP, a WSC-NP3 sample suspension, dosage by 10000mg/kgBW is irritated stomach, irritate stomach 1 time every 4h, carry out altogether 3 times, free diet after the administration, observe 7d then continuously, whether the record mouse spirit, activity, diet abnormal conditions occur in the 7d after being subjected to the reagent thing, and the death condition of mouse respectively organized in record.For the mouse of death the anatomic observation heart, liver, spleen, lung, kidney etc. immediately, record pathology situation.
(4) interpretation
1, the influence to the experimental rat body weight sees Table 1:
Table 1WSC-MP and WSC-NP to the influence of obese rat weight gain (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
As seen from Table 1, compare with the normal group weight gain, the weight gain of high fat group and other all treatment groups all is significantly higher than normal group after the modeling, shows that the fat model of experimental rat is successfully set up.After giving the corresponding treatment medicine respectively, compare with high fat control group with the normal control group, each organizes the effect that all shows obvious inhibition body weight gain each group of WSC-MP and WSC-NP, and with dosage obvious dependency is arranged, promptly along with dosage increase effect is obvious more.But, see in the whole experiment that the antiobesity action of WSC-MP is better than each treatment group of WSC-NP.So weight data shows all body weight gain of energy good restraining obese rat of WSC-MP and WSC-NP, the effect of fat-reducing is arranged, and the antiobesity action of WSC-MP is better than WSC-NP.
2, the food utilization of experimental rat sees Table 2:
Table 2WSC-MP and WSC-NP to the influence of obese rat food utilization (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
Table 2 is rat food utilization correlation circumstances, therefrom compares with normal group, high fat group as can be seen, and except that L-WSC-NP and M-WSC-NP group, the other treatment group all has the effect of inhibition experimental rat appetite in various degree.This shows, all dosage of WSC-MP and the high dosage of WSC-NP all have the effect that suppresses obese rat appetite, and this also is the one of the main reasons that rat body weight reduces that causes fat.And when therapeutic dose increased, it is remarkable that this effect is tending towards.But all in all the restraining effect of WSC-NP is less than WSC-MP.
3, the fat body ratio of experimental rat sees Table 3:
Table 3WSC-MP and WSC-NP to the influence of obese rat fat body ratio (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
As can be seen from Table 3, the fat body of high fat group shows that than apparently higher than other groups all treatment groups all have the effect of good minimizing obese rat body fat.But, between the various dose group of different therapeutants and no significant difference.Experimental result shows that the effect of WSC-MP treatment group is apparently higher than corresponding WSC-NP.So WSC-MP and WSC-NP all have the effect that reduces the obese rat body fat, and the WSC-MP effect is better than WSC-NP.
4, the serum biochemistry index of experimental rat sees Table 4:
Table 4WSC-MP and WSC-NP to the influence of obese rat serum biochemistry index (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
TC data presentation in the table 4: with high fat control group significant difference is arranged more all, illustrate that all treatment groups all have the effect that reduces blood fat in the obese rat body; And the ortho-water soluble chitosan reduces the effect of TC apparently higher than WSC-MP and all dosage groups of WSC-NP.The TG data also demonstrate, and compare with the normal control group, and the ortho-water soluble chitosan possesses good reduction TG effect.But the data of HDL find that but used treatment group all can reduce the intravital HDL level of obese rat.
The LDL data show that all treatment groups all have the effect of LDL level in the good reduction obese rat body, and the effect of ortho-water soluble chitosan is the most obvious; The effect of each dosage group of WSC-MP and WSC-NP all has obvious dosage correlation, i.e. dosage increase effect strengthens.And, when heavy dose, possess the effect of the reduction LDL suitable with the ortho-water soluble chitosan.So WSC, WSC-MP and WSC-NP all can improve the level of obese rat blood fat lipid to a certain extent, possesses the auxiliary effect that reduces the obese rat blood fat.
5, the whole blood viscosity of experimental rat sees Table 5:
Table 5WSC-MP and WSC-NP to the influence of obese rat whole blood viscosity (means+SE, n=10)
Annotate: have significant difference (p＜0.05) in the same column data between different letter representation data
As seen from Table 5, WSC, WSC-MP compare with high fat control group and no significant difference with normal group the whole blood viscosity influence of obese rat with WSC-NP.Show that these therapeutants may well not reduce the effect of obese rat whole blood viscosity.
6, toxicity test result
The mortality ratio of WSC does not reach the lethal quantity of half, so the LD of WSC
50Should be greater than 10000mg/kg.And the WSC-NP mortality ratio is 65%, table look-up LD
50=2370mg/kg.The mortality ratio of WSC-MP is 55%, table look-up LD
50=4080mg/kg.Toxicity result shows that WSC is actual non-toxic substance, and WSC-MP and WSC-NP are low toxicity material.
This experimental result shows, all growths of the body weight of energy good restraining obese rat of WSC, WSC-MP and WSC-NP in experimentation all around, each treatment group effect of WSC-MP is better than the antiobesity action of each treatment group of WSC-NP, and the restraining effect of the middle high dose group of WSC-MP and WSC-NP and WSC is suitable.Find that by observation except that M-WSC-NP and L-WSC-NP group, the reason that the other treatment group of WSC, WSC-MP and WSC-NP suppresses the obese rat body weight gain is the appetite that has suppressed obese rat to food utilization in the experimentation.Body fat data show that WSC-MP and WSC-NP all have the effect that reduces the obese rat body fat, and the WSC-MP effect is better than WSC-NP.Blood fat biochemical indicator data show that WSC, WSC-MP and WSC-NP possess the effect of auxiliary antilipemic.
Claims (7)
1. the preparation method of a water-soluble chitosan particulate is that water-soluble chitosan is water-soluble, adopts spray drying method for preparation to obtain; It is characterized in that described water-soluble chitosan deacetylation scope be 60%～99% and molecular weight be 1～3,000,000.
2. according to the preparation method of the described water-soluble chitosan particulate of claim 1, it is characterized in that described water-soluble chitosan deacetylation scope be 85%～99% and molecular weight be 10～500,000.
3. the preparation method of a water-soluble chitosan particulate, be with polyphosphoric acid sodium solution and water-soluble chitosan solution generation ionomer after spray drying method for preparation obtains, it is characterized in that described water-soluble chitosan deacetylation scope be 60%～99% and molecular weight be 1～3,000,000.
4. according to the preparation method of the described water-soluble chitosan particulate of claim 3, it is characterized in that described water-soluble chitosan deacetylation scope be 85%～99% and molecular weight be 10～500,000.
5. the application of the water-soluble chitosan particulate for preparing of a claim 1,2,3 or 4 described methods is characterized in that in preparation fat-reducing or the medicine of lipopenicillinase or the application aspect the food.
6. application according to claim 5 is characterized in that the water-soluble chitosan particulate that claim 1 is prepared is applied to prepare the medicine or the food aspect of depress appetite.
7. application according to claim 5 is characterized in that the water-soluble chitosan particulate that claim 1 is prepared is applied to prepare medicine or the food aspect that reduces body fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105058496A CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105058496A CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102010512A true CN102010512A (en) | 2011-04-13 |
| CN102010512B CN102010512B (en) | 2012-12-12 |
Family
ID=43840856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105058496A Expired - Fee Related CN102010512B (en) | 2010-10-12 | 2010-10-12 | Preparation method and application of water-soluble chitosan micro-particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102010512B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293752A (en) * | 2011-08-26 | 2011-12-28 | 广东药学院 | Preparation method of chitosan-carried capsaicin microsphere as well as microsphere and application of microsphere to weight reduction and sugar reduction |
| CN102389398A (en) * | 2011-08-26 | 2012-03-28 | 广东药学院 | Chitosan-loaded capsaicin microspheres, preparation method thereof, and application thereof |
| CN102728079A (en) * | 2012-06-21 | 2012-10-17 | 厦门蓝湾科技有限公司 | Drying method of water-soluble low molecular weight chitosan |
| WO2014187362A1 (en) * | 2013-05-23 | 2014-11-27 | Taiwan Hopax Chems. Mfg. Co., Ltd. | Composition for body fat consumption |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060016164A (en) * | 2004-08-17 | 2006-02-22 | 학교법인 성균관대학 | Porous hydrogels using glycol chitosan for gastric retention device |
| CN101732257A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan nanoparticle and preparation method and application thereof |
| CN101732259A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan micron particle as well as preparation method and application thereof |
-
2010
- 2010-10-12 CN CN2010105058496A patent/CN102010512B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060016164A (en) * | 2004-08-17 | 2006-02-22 | 학교법인 성균관대학 | Porous hydrogels using glycol chitosan for gastric retention device |
| CN101732257A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan nanoparticle and preparation method and application thereof |
| CN101732259A (en) * | 2009-12-29 | 2010-06-16 | 广东药学院 | Chitosan micron particle as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《中国优秀硕士学位论文全文数据库 医药卫生科技辑（2009年）》 20090815 宋涛 壳聚糖以及衍生物对大鼠肥胖的治疗与预防作用研究 摘要及正文第16-28页 1-5,7 , 第8期 2 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293752A (en) * | 2011-08-26 | 2011-12-28 | 广东药学院 | Preparation method of chitosan-carried capsaicin microsphere as well as microsphere and application of microsphere to weight reduction and sugar reduction |
| CN102389398A (en) * | 2011-08-26 | 2012-03-28 | 广东药学院 | Chitosan-loaded capsaicin microspheres, preparation method thereof, and application thereof |
| CN102728079A (en) * | 2012-06-21 | 2012-10-17 | 厦门蓝湾科技有限公司 | Drying method of water-soluble low molecular weight chitosan |
| WO2014187362A1 (en) * | 2013-05-23 | 2014-11-27 | Taiwan Hopax Chems. Mfg. Co., Ltd. | Composition for body fat consumption |
| TWI581798B (en) * | 2013-05-23 | 2017-05-11 | 聚和國際股份有限公司 | Composition for body fat consumption |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102010512B (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106580919B (en) | A kind of ganoderma lucidum spore oil microcapsule powder and its preparation method and application | |
| CN102010512B (en) | Preparation method and application of water-soluble chitosan micro-particles | |
| CN102885060A (en) | Avermectin nanometer microemulsion and preparation method thereof | |
| CN102215850A (en) | A composition comprising extraction of fucoxanthin | |
| CN105832675B (en) | A kind of load selenium chitosan microball of controllable sustained-release selenium anion and preparation method thereof | |
| CN104337851A (en) | Preparation method of oleum fructus bruceae nano structure lipid carrier and freeze-dried powder thereof | |
| de Morais et al. | Nanoencapsulation of the bioactive compounds of Spirulina with a microalgal biopolymer coating | |
| CN103316031B (en) | Weight reduction and body fat reduction applications of chitosan oligosaccharide | |
| CN109893513B (en) | Composite haematococcus pluvialis astaxanthin self-emulsifying soft capsule and preparation method and application thereof | |
| CN107281494B (en) | Preparation method and application of graphene oxide-protamine/sodium alginate compound | |
| CN115364054A (en) | Colon-targeted oil-in-water Pickering emulsion based on shellac nanoparticles and chitosan, and preparation and application thereof | |
| CN101732259B (en) | Chitosan micron particle as well as preparation method and application thereof | |
| CN101978954B (en) | Preparation and application of chitosan particles | |
| CN101810577B (en) | Gossypol intravenous injection fatty emulsion for curing tumors | |
| CN103690580A (en) | Microemulsion extraction method and microemulsion extract of Andrographis paniculata | |
| CN105963254A (en) | Coenzyme Q10 pharmaceutical composition and preparation process thereof | |
| CN102058530A (en) | Ganoderma lucidum polysaccharide oral nanoemulsion and preparation method thereof | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN109157549A (en) | EGCG G. lucidum spores Softgel and preparation method thereof | |
| WO2020253709A1 (en) | Method for preparing transparent water dispersion of fat-soluble nutritional medicine | |
| CN109224083B (en) | Application of poloxamer-modified iron oxide nanoparticles in preparation of drugs for treating non-alcoholic fatty liver diseases | |
| CN104055731B (en) | A kind of coccidiostat fluoroadenine solution and preparation method thereof | |
| CN105919974B (en) | Salmon calcitonin phosphatide complexes and its lipid nano particle and preparation method | |
| CN105106950B (en) | A kind of immunologic adjuvant of live vaccine, preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510006 Guangdong City, Guangzhou province outside the University of East Ring Road, No. 280 Patentee after: GUANGDONG PHARMACEUTICAL University Address before: 510006 Guangdong City, Guangzhou province outside the University of East Ring Road, No. 280 Patentee before: Guangdong Pharmaceutical University |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121212 |